2-(5-phenoxyoxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane | 1206716-79-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(5-phenoxyoxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane
• 英文别名: 2-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-5-phenoxy-[1,3]oxazolo[4,5-b]pyridine
• CAS: 1206716-79-1
• 化学式: C₁₉H₂₀N₄O₂
• 分子量: 336.393
• InChiKey: JLUNJQZXCXTHSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  54.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(5-phenoxyoxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-(5-phenoxyoxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane hydrochloride
  参考文献：
  名称：

  Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

  摘要：

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm9015075
• 作为产物：
  描述：

  2-(5-bromooxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane 、 苯酚 在 tetramethylheptane-3,5-dione 、 caesium carbonate 、 copper(l) chloride 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 4.0h， 以32%的产率得到2-(5-phenoxyoxazolo[4,5-b]pyridin-2-yl)-2,5-diazabicyclo[3.2.2]nonane
  参考文献：
  名称：

  Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

  摘要：

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm9015075

文献信息

• Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
  作者：Christopher J. O’Donnell、Bruce N. Rogers、Brian S. Bronk、Dianne K. Bryce、Jotham W. Coe、Karen K. Cook、Allen J. Duplantier、Edelweiss Evrard、Mihaly Hajós、William E. Hoffmann、Raymond S. Hurst、Noha Maklad、Robert J. Mather、Stafford McLean、Frank M. Nedza、Brian T. O’Neill、Langu Peng、Weimin Qian、Melinda M. Rottas、Steven B. Sands、Anne W. Schmidt、Alka V. Shrikhande、Douglas K. Spracklin、Diane F. Wong、Andy Zhang、Lei Zhang

  DOI：10.1021/jm9015075

  日期：2010.2.11

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.